(Q36139512)

12 August 2017

1 reference

title

Recombinant approaches to IgG-like bispecific antibodies (English)

1 reference

12 August 2017

1 reference

Jonathan S Marvin

1

1 reference

12 August 2017

Zhenping Zhu

series ordinal

2

1 reference

12 August 2017

publication date

1 June 2005

1 reference

Acta Pharmacologica Sinica

12 August 2017

published in

1 reference

12 August 2017

volume

26

1 reference

12 August 2017

issue

6

1 reference

12 August 2017

page(s)

649-658

1 reference

https://scigraph.springernature.com/pub.10.1111/j.1745-7254.2005.00119.x

12 August 2017

exact match

0 references

cites work

In-vitro protein evolution by ribosome display and mRNA display

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

TRAIL and its receptors as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Bispecific antibody conjugates in therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Bispecific antibody targeting of doxorubicin to carcinoembryonic antigen-expressing colon cancer cell lines in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Toward the production of bispecific antibody fragments for clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Design and application of diabodies, triabodies and tetrabodies for cancer targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Recombinant bispecific antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

An efficient route to human bispecific IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

"Diabodies": small bivalent and bispecific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

High level secretion of a humanized bispecific diabody from Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Di-diabody: a novel tetravalent bispecific antibody molecule by design

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Stability engineering of antibody single-chain Fv fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Single domain antibodies: comparison of camel VH and camelised human VH domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Design, Construction, and In Vitro Analyses of Multivalent Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

Hybrid hybridomas and their use in immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00119.X

10.1111/J.1745-7254.2005.00119.X

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

12 August 2017

1040765598

0 references

1 reference